ZILBRYSQ

This brand name is authorized in United States. It is also authorized in Croatia, Estonia, France, Lithuania, Romania.

Active ingredients

The drug ZILBRYSQ contains one active pharmaceutical ingredient (API):

1	Zilucoplan UNII YG391PK0CC - ZILUCOPLAN
	Zilucoplan is a 15 amino acid, synthetic macrocyclic peptide that inhibits the effects of the complement protein C5 through a dual mechanism of action. It specifically binds to C5, thereby inhibiting its cleavage by the C5 convertase to C5a and C5b, which results in a downregulation of the assembly and cytolytic activity of the membrane attack complex (MAC). Additionally, by binding to the C5b moiety of C5, zilucoplan sterically hinders binding of C5b to C6, which prevents the subsequent assembly and activity of the MAC, should any C5b be formed.
	Read more about Zilucoplan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZILBRYSQ Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AJ06		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3057667, 3057678, 3057689, 3057803, 3057814, 3057825
FR	Base de données publique des médicaments	67028747, 68906518, 69339825
LT	Valstybinė vaistų kontrolės tarnyba	1098278, 1098279, 1098280, 1098281, 1098282, 1098283
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69900001, W69901001, W69902001
US	FDA, National Drug Code	50474-990, 50474-991, 50474-992